Introduction
Anaemia of chronic disease (ACD) is a common extra-articular manifestation of active rheumatoid arthritis (RA). Cytokines such as interleukin 1 beta (IL-113) and tumour necrosis factor alpha (TNFe) are immunoregulatory factors and may be involved in the pathogenesis of rheumatic diseases and ACD [1] [2] [3] [4] . ACD is associated with inflammatory conditions associated with macrophage activation. Activated macrophages produce a number of cytokines including IL-1, TNF~, interferon alpha and gamma (IFNa, IFNT), which may have an affect on erythropoiesis [5, 6] , thereby participating in the development of ACD. Previous in vitro studies have shown the inhibition of CFUe and BFUe by TNF~ [7] [8] [9] [10] [11] . Whether these effects of TNF~ on erythroid progenitors are direct [8] or whether the presence of other cells is required [10, 11] is not entirely clear. In addition, chronic TNF~ exposure has been shown to suppress erythropoiesis in vivo [12, 13] . Nude mice inoculated with Chinese hamster ovary (CHO) cells expressing the human TNFe gene developed a hypoferraemic, hypoproliferative anaemia with normal iron stores and decreased numbers of bone marrow and splenic CFUe and BFUe. These data suggest that chronic TNFc~ exposure in vivo may be involved in the development of ACD. Serum TNFc~ concentration has been shown to be elevated in RA patients with ACD and correlates well with RA disease parameters [14] . Based on the inverse correlation of serum TNFe and haemoglobin in the above-mentioned study [14] and in a group of HIV patients [15] , it may be argued that TNFc~ plays a specific role in ACD.
Low plasma erythropoietin (EPO) levels in relation to the degree of anaemia in patients with acute or chronic tion, inflammation or malignancy despite a normal renal function [16] [17] [18] [19] [20] . Therefore, it is postulated that ACD patients are characterised by a relatively low EPO production. Decreased EPO sensitivity progenitors is postulated in RA and ACD [19] . ACD can be corrected with recombinant human EPO (r-h-EPO) therapy in patients with RA [20] [21] [22] [23] [24] [25] . It has already been demonstrated that anaemia in mice caused exclusively by chronic TNF exposure can be corrected by administration of exogenous EPO [25] . Therefore, one may postulate that the beneficial effects of EPO on ACD in RA patients can be explained, at least to some extent, by the ability of EPO to conteract TNF-mediated suppression of erythropoiesis. Therefore, we studied whether the suppressive effects of TNFe on erythropoiesis in vitro could be corrected with increasing r-h-EPO concentrations. We were also interested in possible differences between TNFe-inhibited CFUe and BFUe colony growth and whether these effects would differ between RA patients with ACD and RA patients without anaemia.
was a indicated in the figures. R-h-EPO (Boehringer, Mannheim) was used as shown in Fig. 1 .
Colony culture assay
Progenitor cells (0.5-1 x 105 cells/ml) of eight ACD patients and eight control patients were cultured in a mixture of Iscove's modified Dulbecco's medium (IMDM), 1.1% methylcellulose, 30% fetal calf serum (FCS), bovine serum albumin (BSA), transferrin, lecithin, sodium selenite and 2-mercaptoethanol in a humidified atmosphere of 5% CO 2 in air at 37 ~ as reported previously [25] . Increasing concentrations of r-h-EPO (0.25; 0.5; 1; 2 U/ml), each in combination with increasing concentrations of TNF~ (0; 50; 100; 200; 400 U/ml) were added to the cultures. CFUe and BFUe were scored after 7 and 14 days, respectively.
Statistics
The Wilcoxon signed-rank test was used to calculate statistical differences between the number of CFUe or BFUe under different conditions of incubation within one group. To established differences in CFUe or BFUe between the two groups, the two-sample Wilcoxon rank sum test was used.
Patients and methods

Preparation of cell suspension
Bone marrow (BM) of eight RA patients with ACD (group 1) and eight RA patients without anaemia (control patients; group 2) was aspirated from the posterior iliac crest after the patients had given informed consent. The marrow was collected in Hank's balanced solution (HBBS) with heparin, diluted in HBBS, and mononuclear ceils were separated over Ficoll-Isopaque (1.077 g/cm2; Nycomed, Oslo, Norway).
Recombinant human cytokines
Recombinant human TNFe (1 U/ml is 16 pg/ml) was provided by Boehringer Institute (Vienna, Austria). The concentration of TNFe
Results
Inhibition of erythropoiesis by TNFc~ in vitro
TNFe suppressed CFUe and BFUe growth in a dosedependent manner (Tables I and 2 ; Fig. 1 ). The same inhibition occurred in both groups.
Effect of r-h-EPO and CFUe and BFUe
After the addition of increasing concentrations of r-h-EPO (0.25 U/ml up to 2 U/ml) the number of CFUe and BFUe increased in a dose-dependent manner. In cultures 
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TNFe are defined as 100%. A CFUe colony formation in anaemia of chronic disease (ACD) patients (group 1); B CFUe colony formation ion control patients (group 2); C BFUe colony formation in group 1; D BFUe colony formation in group 2. Increasing concentrations of TNF~ were combined with four different concentration of r-h-EPO: (o) 0.25 U/ml; ([) 0.5 U/ml; (,) 1 U/ml; (n) 2 U/ml from both groups with 2 U/ml r-h-EPO and no TNFe, we found a significantly higher CFUe score as compared to cultures incubated with 0.25 U/ml r-h-EPO. N o significant differences between the groups (Tables 1 and 2 ; Fig. 1 ) were demonstrated.
Effect ofr-h-EPO on TNFe-suppressed CFUe and BFUe
TNFc~ suppression was corrected with the addition of excess r-h-EPO as shown in Tables 1 and 2 and Fig. 1 . Regarding CFUe (in group 1), incubation with 0.25 U/ml * P < 0.05 (compared to basic culture where 0.25 U/ml EPO was added without change in TNFc~ concentration) ** P < 0.05 (compared to basic culture where no TNFe was added and no change in EPO concentration)
r-h-EPO, and 50 U/ml and 400 U/ml TNFc~ gave suppression of 28% and 49%, respectively, compared to the culture without TNF~. Increasing the concentration of r-h-EPO from 0.25 U/ml to 2 U/ml resulted in complete correction of inhibition when 50 U/ml TNFe was used and partial correction of the TNFe suppression to 28% when 400 U/ml TNFc~ was added to the cultures. Similar results were obtained in group 2. The correction of TNFe inhibition also occurred in BFUe cultures. Regarding BFUe (in group 1), incubation with 0.25 U/ml r-h-EPO, and 50 U/ml and 400 U/ml TNF~ resulted in suppression of 33% and 61%, respectively, as compared to the cultures without TNFe. Increasing the concentration of r-h-EPO from 0.25 U/ml to 2U/ml diminished the suppression to 17% (50 U/ml TNFe) and 55% (400 U/ml TNF~). BFUe growth was significantly more inhibited as compared to CFUe at similar TNFe concentrations. CFUe suppression was counteracted more by higher concentrations of r-h-EPO than was BFUe suppression.
Discussion
Many theories exist to explain the pathogenesis of ACD, including an impaired EPO production, decreased bone marrow sensitivity to EPO and inhibition of erythroid progenitors by cytokines such as TNFe. Our study demonstrated that TNFe indeed suppressed erythropoiesis (CFUe and BFUe) in vitro and this inhibition was partly reversed by increased concentrations of r-h-EPO.
The mechanism by which this effect occurs is unknown at the present. It could be speculated that EPO causes a down-regulation of TNFe receptor expression on BFUe and CFUe, thus reducing the response to the inhibitor. Alternatively, TNFc~ may down-regulate EPO receptor expression on BFUe and CFUe, with the CFUe and BFUe requiring higher r-h-EPO concentrations for optimum colony formation. Possible interactions of EPO and TNFe, as well as other cytokines such as IFN7 [27] , on receptor levels will be subjects of future studies. On the other hand, the inhibitory effects of TNFe could be enhanced by a TNFe-mediated release of other cytokines in the cultures, such as IL-1 and IFNy, causing additional suppression of erythropoiesis [28] .
We demonstrated that the CFUe colony growth inhibition by a low concentration of TNFe (50 U/ml) was completely restored when r-h-EPO was increased from 0.25 U/ml to 2 U/ml. Apparently, in cultures where higher concentrations of TNFc~ were added, r-h-EPO was not able to counteract inhibition completely. Similar results have been shown by Means [27] who showed that r-h-IFNT-related inhibition of CFUe colony growth is reversed by increased concentrations of r-h-EPO. The late erythroid progenitors (CFUe) are more dependent on EPO than earlier progenitors (BFUe), which also require other growth factors (such as IL-3) for differentiation and proliferation. This may explain the better correction of TNF~-inhibited CFUe growth with the addition of r-h-EPO as compared to BFUe growth in our study. We did not establish any differences in CFUe and BFUe growth between RA patients with ACD and RA patients without anaemia. In this in vitro culture system we used much higher concentrations of TNFe and EPO than can be expected to be present in vivo, which might explain why no differences were observed between the two groups.
Johnson et al. [25] have reported that, in TNFc~-treated mice, EPO abrogates the TNFc~ suppressive effect in a dose-dependent manner. This observation has been sustained by observations [24] that EPO treatment prevents a decrease in the haematocrit during chronic administration of TNFe [24] . In RA patients, circulating levels of TNF are much lower (max. 50 pg/ml) than those used in the above mentioned study [25] but the local concentra-tion of TNFe in the bone marrow might be higher and thus participate in the pathogenesis of ACD in RA.
Our in vitro data supported the hypothesis of lower levels of EPO [18] , as well as elevated circulating TNFe serum levels [14] , playing an important role in the development of ACD in patients with RA. Further efforts should be directed to demonstrating the relationship between in vitro results and clinical observations.
